Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 9
2015 13
2016 8
2017 4
2018 5
2019 4
2020 6
2021 11
2022 13
2023 21
2024 15
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
Mukherjee D, Previs RA, Haines C, Al Abo M, Juras PK, Strickland KC, Chakraborty B, Artham S, Whitaker RS, Hebert K, Fontenot J, Patierno SR, Freedman JA, Lau FH, Burow ME, Chang CY, McDonnell DP. Mukherjee D, et al. Among authors: previs ra. Cancer Res. 2023 Sep 1;83(17):2889-2907. doi: 10.1158/0008-5472.CAN-22-1622. Cancer Res. 2023. PMID: 37335130 Free PMC article.
Recent Advances in Gynecological Malignancies: Focus on ASCO 2023.
Bodriagova O, Previs RA, Gaba L, Shankar A, Vidal L, Saini KS. Bodriagova O, et al. Among authors: previs ra. Oncol Ther. 2023 Dec;11(4):397-409. doi: 10.1007/s40487-023-00244-5. Epub 2023 Sep 15. Oncol Ther. 2023. PMID: 37715082 Free PMC article. No abstract available.
Adnexal Masses in Pregnancy.
Montes de Oca MK, Dotters-Katz SK, Kuller JA, Previs RA. Montes de Oca MK, et al. Among authors: previs ra. Obstet Gynecol Surv. 2021 Jul;76(7):437-450. doi: 10.1097/OGX.0000000000000909. Obstet Gynecol Surv. 2021. PMID: 34324696
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Fu S, et al. Among authors: previs ra. J Clin Oncol. 2023 Mar 20;41(9):1725-1734. doi: 10.1200/JCO.22.00830. Epub 2022 Dec 5. J Clin Oncol. 2023. PMID: 36469840 Free PMC article. Clinical Trial.
OX40/OX40 ligand and its role in precision immune oncology.
Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. Thapa B, et al. Among authors: previs ra. Cancer Metastasis Rev. 2024 Sep;43(3):1001-1013. doi: 10.1007/s10555-024-10184-9. Epub 2024 Mar 25. Cancer Metastasis Rev. 2024. PMID: 38526805 Free PMC article. Review.
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
Seager RJ, Ko H, Pabla S, Senosain MF, Kalinski P, Van Roey E, Gao S, Strickland KC, Previs RA, Nesline MK, Hastings S, Zhang S, Conroy JM, Jensen TJ, Eisenberg M, Caveney B, Severson EA, Ramkissoon S, Gandhi S. Seager RJ, et al. Among authors: previs ra. J Pers Med. 2024 Apr 30;14(5):481. doi: 10.3390/jpm14050481. J Pers Med. 2024. PMID: 38793063 Free PMC article.
103 results